Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYP0322 in ROS1+ Solid Tumors
NCT06128148Phase 1Recruiting
- Sponsor
- Guangzhou JOYO Pharma
- Start
- May 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JYP0322 in solid tumor, non-small cell lung cancer (NSCLC) and glioma (7 arms), sponsored by Guangzhou JOYO Pharma. Primary endpoint: Frequency and severity of adverse events up to 36 months. Started May 2022; status: recruiting.
02
Drugs
JYP0322
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)glioma
Beyond the preview
Go deeper on NCT06128148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128148.